Johnson & Johnson JNJ is set to announce its third quarter earnings on Oct. 15 before the market opens. Wall Street is expecting the pharmaceutical and healthcare giant to post earnings per share (EPS) of $2.21 and revenue of $22.16 billion.

强生JNJ将于10月15日开市前公布其第三季度收益。华尔街预计，这家制药和医疗保健巨头的每股收益（EPS）将达到22.1亿美元，收入将达到221.6亿美元。

But while J&J's numbers are in focus, recent headlines about its MedTech acquisitions and drug trial halts are stealing the spotlight.

但是，尽管强生的数字备受关注，但最近有关其医疗技术收购和药物试验停止的头条新闻正在抢占聚光灯。

MedTech Grows, Drug Trials Stumble

MedTech成长，药物试验步履蹒跚

Johnson & Johnson recently completed its acquisition of V-Wave, adding a minimally invasive cardiovascular treatment to its MedTech portfolio. The Ventura Interatrial Shunt is expected to strengthen J&J's position in tackling heart failure, but the acquisition comes with a short-term cost. The company has warned that this move will dilute adjusted EPS by around 24 cents in 2024 and 6 cents in 2025, an update they'll likely address in Tuesday’s earnings report..

强生公司最近完成了对V-Wave的收购，在其MedTech投资组合中增加了微创心血管治疗。预计文图拉房间分流术将加强强生公司在治疗心力衰竭方面的地位，但收购带来的是短期成本。该公司警告称，这一举措将在2024年和2025年分别稀释调整后每股收益约24美分和6美分，他们可能会在周二的收益报告中对此进行更新。。

On the flip side, the company had to discontinue its Phase 3 SunRISe-2 trial, which was investigating a treatment for muscle-invasive bladder cancer. The trial didn't show superiority over chemoradiation, leading to its early termination, though J&J remains optimistic about the future of its TARIS platform, forecasting a $5 billion potential..

另一方面，该公司不得不停止其3期SunRISe-2试验，该试验正在研究肌肉浸润性膀胱癌的治疗方法。尽管强生对其TARIS平台的未来仍持乐观态度，预计其潜力将达到50亿美元，但该试验并未显示出优于放化疗的优势，因此提前终止了试验。。

The Charts Are Sending Mixed Signals

图表发出了混合信号

Despite some positive news in the MedTech arena, Johnson & Johnson’s stock has had a relatively stagnant year, up just 0.93% year-to-date and only 2.49% over the past year. But in the past six months, the stock has seen a 9.40% rise, reflecting a slow but steady recovery.

尽管MedTech领域有一些积极消息，强生公司的股票今年相对停滞不前，今年迄今仅上涨0.93%，去年仅上涨2.49%。但在过去的六个月里，该股上涨了9.40%，反映出缓慢但稳定的复苏。

Chart created using Benzinga Pro

使用Benzinga Pro创建的图表

At its current price of $161.46, JNJ stock is just above its eight-day simple moving average of $160.48, a positive sign. However, the stock is lagging behind its 20-day and 50-day simple moving averages, sitting at $162.32 and $162.53, respectively. This signals some underlying selling pressure that may persist in the near term..

JNJ股价目前为161.46美元，略高于其8天简单移动平均线160.48美元，这是一个积极的迹象。然而，该股落后于其20天和50天简单移动平均线，分别为162.32美元和162.53美元。这表明一些潜在的销售压力可能在短期内持续存在。。

Read Also: What Analysts Are Saying About Johnson & Johnson Stock

另请阅读：分析师对强生股票的看法

Chart created using Benzinga Pro

使用Benzinga Pro创建的图表

The Moving Average Convergence/Divergence (MACD) indicator at a negative 0.72 leans toward bearishness, hinting at continued downward pressure. Meanwhile, JNJ stock's Relative Strength Index (RSI) of 47.83 suggests the stock is in neutral territory.

移动平均收敛/发散（MACD）指数为负0.72，倾向于看跌，暗示持续下行压力。与此同时，JNJ股票的相对强度指数（RSI）为47.83，表明该股处于中性区域。

The Bollinger Bands show a range between $157.98 and $168.05, with JNJ stock nestled in the lower bearish band. This positioning could suggest that the stock is poised for a bounce, but given the selling pressure, caution is warranted.

布林格带显示在157.98美元至168.05美元之间，JNJ股票位于较低的熊市带。这种定位可能表明该股已做好反弹的准备，但鉴于抛售压力，有必要谨慎行事。

Can Q3 Earnings Change The Tune?

第三季度盈利能否改变现状？

All eyes will be on J&J's third-quarter earnings report. Investors are particularly interested in any updates to the company's guidance following the V-Wave acquisition and the ongoing performance of its MedTech and Innovative Medicine segments.

所有的目光都将集中在强生公司的第三季度盈利报告上。投资者特别感兴趣的是，在收购V-Wave以及其医疗技术和创新医学部门的持续表现之后，公司指南的任何更新。

Johnson & Johnson's charts may not be flashing strong bullish signals, but its strategic moves in MedTech and future product pipeline could offer long-term growth potential.

强生公司的图表可能没有显示出强烈的看涨信号，但其在MedTech和未来产品线方面的战略举措可能提供长期增长潜力。

Investors will have to weigh the upcoming earnings report to see if J&J stock can shake off recent pressures and revitalize its performance.

投资者将不得不权衡即将发布的收益报告，看看强生股票能否摆脱近期的压力，重振业绩。

Read Next:

阅读下一页：

World’s Third-Largest OTC Player Sanofi’s Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice

世界第三大非处方药公司赛诺菲的消费者健康部门与克莱顿·杜比利埃和赖斯达成160亿美元的交易

Photo: ShutterstockMarket News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

照片：Benzinga API为您带来的ShutterstockMarket新闻和数据©2024 Benzinga.com。Benzinga不提供投资建议。保留所有权利。